SCHEMBL9997237

SCHEMBL9997237

CC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(C(=O)O)c(O)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APAF1 O14727 1/20 0.67
CASP6 P55212 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
MCL1 Q07820 1/20 0.65
PKM P14618 1/20 0.63
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
GAA P10253 1/20 0.59
GFER P55789 1/20 0.59
LMNA P02545 3/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
ALDH1A1 P00352 2/20 0.59
HSD17B10 Q99714 1/20 0.59
ALOX15 P16050 1/20 0.59
MAPK1 P28482 1/20 0.59
HTT P42858 1/20 0.59
PTPN5 P54829 1/20 0.56
RAB9A P51151 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15056016 0.87 SMN1; SMN2 (0.70) PKMMEN1KMT2ALMNASMN1; SMN2
SCHEMBL1130086 0.86 MCL1 (0.68) MCL1MEN1KMT2AGFERALDH1A1
SCHEMBL9997330 0.85 MCL1 (0.70) MCL1MEN1KMT2AGAAGFER
SCHEMBL7828166 0.84 MCL1 (0.78) APAF1CASP6TDP1L3MBTL1MCL1
SCHEMBL11888673 0.84 MEN1 (0.61) CASP6L3MBTL1PKMMEN1KMT2A
SCHEMBL150434 0.83 MCL1 (0.68) MCL1MEN1KMT2AGAAALDH1A1
SCHEMBL9997075 0.83 MCL1 (0.68) MCL1MEN1KMT2AALDH1A1HSD17B10
SCHEMBL9997160 0.83 HSD17B10 (0.70) MCL1MEN1KMT2AALDH1A1HSD17B10
SCHEMBL9997129 0.83 PFKFB3 (0.62) APAF1CASP6TDP1L3MBTL1MCL1
SCHEMBL15055864 0.83 SMN1; SMN2 (0.69) PKMLMNASMN1; SMN2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 EP claimed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed